Bridging the gap in rheumatoid arthritis treatment with hyaluronic acid-based drug delivery approaches

IF 7.7 1区化学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY International Journal of Biological Macromolecules Pub Date : 2024-05-23 DOI:10.1016/j.ijbiomac.2024.132586

Sakshi Priya , Jeevika Daryani , Vaibhavi Meghraj Desai, Gautam Singhvi

{"title":"Bridging the gap in rheumatoid arthritis treatment with hyaluronic acid-based drug delivery approaches","authors":"Sakshi Priya , Jeevika Daryani , Vaibhavi Meghraj Desai, Gautam Singhvi","doi":"10.1016/j.ijbiomac.2024.132586","DOIUrl":null,"url":null,"abstract":"<div><p>Rheumatoid Arthritis (RA) is a chronic, inflammatory, auto-immune disease that is majorly associated with the degradation of the synovial linings of the joints. It is a progressive disease that reduces the life span in affected individuals. Nanoparticles involving hyaluronic acid (HA) have gained the limelight for designing target-specific and more effective drug delivery options for RA. HA is found abundantly in the synovial fluid and acts as a natural ligand for the CD44 receptors. The targeted delivery approach using CD44 as the target can help in minimizing off-target drug distribution. These HA-based surface-decorated nanocarriers, hydrogels, and MNs are cutting-edge strategies that promise tailored delivery, fewer side effects, and more patient adherence to address the common issues associated with RA therapy. Considering the above facts, this review attempts to discuss the role of HA in making more effective formulations for therapeutic delivery in treating RA. Additionally, it provides a comprehensive overview of the potential advancements, mainly in treating RA by HA-based topical, transdermal, and parenteral drug delivery systems, with relevant case studies. The existing difficulties and potential paths for future research on HA-based non-conventional formulations for the management of RA are also discussed.</p></div>","PeriodicalId":333,"journal":{"name":"International Journal of Biological Macromolecules","volume":null,"pages":null},"PeriodicalIF":7.7000,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Macromolecules","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0141813024033919","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Rheumatoid Arthritis (RA) is a chronic, inflammatory, auto-immune disease that is majorly associated with the degradation of the synovial linings of the joints. It is a progressive disease that reduces the life span in affected individuals. Nanoparticles involving hyaluronic acid (HA) have gained the limelight for designing target-specific and more effective drug delivery options for RA. HA is found abundantly in the synovial fluid and acts as a natural ligand for the CD44 receptors. The targeted delivery approach using CD44 as the target can help in minimizing off-target drug distribution. These HA-based surface-decorated nanocarriers, hydrogels, and MNs are cutting-edge strategies that promise tailored delivery, fewer side effects, and more patient adherence to address the common issues associated with RA therapy. Considering the above facts, this review attempts to discuss the role of HA in making more effective formulations for therapeutic delivery in treating RA. Additionally, it provides a comprehensive overview of the potential advancements, mainly in treating RA by HA-based topical, transdermal, and parenteral drug delivery systems, with relevant case studies. The existing difficulties and potential paths for future research on HA-based non-conventional formulations for the management of RA are also discussed.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用基于透明质酸的给药方法弥合类风湿性关节炎治疗中的差距

类风湿性关节炎（RA）是一种慢性、炎症性、自身免疫性疾病，主要与关节滑膜退化有关。它是一种渐进性疾病，会缩短患者的寿命。涉及透明质酸（HA）的纳米颗粒已成为设计治疗 RA 的靶向特异性和更有效给药方案的焦点。透明质酸大量存在于滑液中，是 CD44 受体的天然配体。以 CD44 为靶点的靶向给药方法有助于最大限度地减少药物的脱靶分布。这些基于 HA 表面装饰的纳米载体、水凝胶和 MN 是最前沿的策略，有望实现定制给药、减少副作用和提高患者依从性，从而解决与 RA 治疗相关的常见问题。考虑到上述事实，本综述试图讨论 HA 在制作更有效的治疗配方以治疗 RA 方面的作用。此外，本综述还通过相关案例研究，全面概述了以HA为基础的局部、透皮和肠外给药系统在治疗RA方面的潜在进展。此外，还讨论了基于HA的非常规制剂在治疗RA方面的现有困难和未来研究的潜在途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International Journal of Biological Macromolecules 生物-生化与分子生物学

CiteScore

13.70

自引率

9.80%

发文量

2728

审稿时长

64 days

期刊介绍： The International Journal of Biological Macromolecules is a well-established international journal dedicated to research on the chemical and biological aspects of natural macromolecules. Focusing on proteins, macromolecular carbohydrates, glycoproteins, proteoglycans, lignins, biological poly-acids, and nucleic acids, the journal presents the latest findings in molecular structure, properties, biological activities, interactions, modifications, and functional properties. Papers must offer new and novel insights, encompassing related model systems, structural conformational studies, theoretical developments, and analytical techniques. Each paper is required to primarily focus on at least one named biological macromolecule, reflected in the title, abstract, and text.